Suchergebnisse - "Armuzzi, Alessandro"

PubPharm (32)

1

Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trials

enthalten in: BMC gastroenterology | 2024

von Peyrin-Biroulet, L. | Arkkila, P. | Armuzzi, A. | +14

2

Effectiveness and Safety of Switching from Intravenous to Subcutaneous Vedolizumab Formulation in Inflammatory Bowel Disease Patients in Clinical Remission

enthalten in: Journal of gastrointestinal and liver diseases : JGLD | 2023

von Parisio, L. | Settanni, C. | Varca, S. | +14

3

Vedolizumab for the Treatment of Chronic Pouchitis

enthalten in: The New England journal of medicine | 2023

von Travis, S. | Silverberg, M. | Danese, S. | +45

4

The role of ustekinumab and vedolizumab in management of extra intestinal manifestations in inflammatory bowel disease

enthalten in: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver | 2023

von Katsanos, K. | Fousekis, F. | Armuzzi, A.

CommentOn: Dig Liver Dis. 2023 Feb;55(2):223-229. - PMID 36241535

5

Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease : the IG-IBD LIVE study

enthalten in: Alimentary pharmacology & therapeutics | 2022

von Pugliese, D. | Privitera, G. | Crispino, F. | +58

CommentIn: Aliment Pharmacol Ther. 2022 Aug;56(4):731-732. - PMID 35879894

6

Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease : a systematic review and meta-analysis

enthalten in: BMC gastroenterology | 2022

von Peyrin-Biroulet, L. | Arkkila, P. | Armuzzi, A. | +13

7

Drug-Related Pneumonitis in Patients Receiving Vedolizumab Therapy for Inflammatory Bowel Disease

enthalten in: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2022

von Pugliese, D. | Privitera, G. | Schepis, T. | +6

8

Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA) : a randomised, double-blind, double-dummy, phase 3 study

enthalten in: The lancet. Gastroenterology & hepatology | 2022

von Danese, S. | Colombel, J. | Lukas, M. | +114

CommentIn: Lancet Gastroenterol Hepatol. 2022 Jan;7(1):2-4. - PMID 34798035

9

Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY) : a phase 3, randomised, controlled trial

enthalten in: The lancet. Gastroenterology & hepatology | 2022

von Peyrin-Biroulet, L. | Hart, A. | Bossuyt, P. | +114

CommentIn: Lancet Gastroenterol Hepatol. 2022 Jan;7(1):2-4. - PMID 34798035

10

Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases : a real-life multicenter, observational study in Italy

enthalten in: Expert opinion on biological therapy | 2022

von Tursi, A. | Mocci, G. | Allegretta, L. | +52